Read + Share
Moens A, Verstockt B, Alsoud D, Sabino J, et al. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as
First-line Biological in Moderate to Severe IBD. Inflamm Bowel Dis 2022;28:1135-1142.
PMID: 34751766
|
 |
|
Moens A, Verstockt B, Alsoud D, Sabino J, et al. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as
First-line Biological in Moderate to Severe IBD. Inflamm Bowel Dis 2022;28:1135-1142.
PMID: 34751766
|
|
|
|